Drugs / Anti-thymocyte globulin (ATG)
Anti-thymocyte globulin (ATG)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00972101 | Sep 2009 → Sep 2011 | disease related to hematopoietic stem cell transplant, leukemia, lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT05579769 | Mar 2023 → May 2024 | myeloid neoplasm | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT07061574 Comparator | Mar 2026 → Apr 2030 expected | type 1 diabetes mellitus | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03734601 Background | Nov 2018 → Dec 2019 | Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +2 | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT01359254 Background | Apr 2010 → Sep 2011 | hematologic disorder | University of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00720629 Comparator | Dec 2007 → Dec 2013 | graft versus host disease | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00176865 Comparator | Aug 2002 → Aug 2012 | Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 3 | NCT00568633 Background | Aug 2007 → Dec 2015 | acute myeloid leukemia | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-thymocyte globulin (ATG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00568633 ↗ |
| Modality | Protein / enzyme biologic | “ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation.” NCT07061574 ↗ |
| Route | Intravenous | “30 mg/kg IV Day -5 through Day -1” NCT00176865 ↗ |